Van Eck Associates Corp Arrowhead Pharmaceuticals, Inc. Transaction History
Van Eck Associates Corp
- $77.4 Billion
- Q1 2025
A detailed history of Van Eck Associates Corp transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Van Eck Associates Corp holds 3,182 shares of ARWR stock, worth $51,548. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,182
Previous 2,978
6.85%
Holding current value
$51,548
Previous $56,000
26.79%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ARWR
# of Institutions
294Shares Held
97.7MCall Options Held
306KPut Options Held
432K-
Black Rock Inc. New York, NY15.7MShares$254 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.2MShares$214 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$180 Million2.29% of portfolio
-
State Street Corp Boston, MA7MShares$113 Million0.0% of portfolio
-
Slate Path Capital LP New York, NY5.23MShares$84.8 Million1.32% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $1.71B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...